Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 HER2 testing in gastric cancer: An update.

Literature DB >> 27217694

HER2 testing in gastric cancer: An update.

Lucas Faria Abrahao-Machado¹, Cristovam Scapulatempo-Neto¹.

Abstract

Human epidermal growth factor receptor 2 (HER2) overexpression is increasingly recognized as a frequent molecular abnormality in gastric and gastroesophageal cancer. With the recent introduction of HER2 molecular targeted therapy for patients with advanced gastric cancer, determination of HER2 status is crucial in order to select patients who may benefit from this treatment. This paper provides an update on our knowledge of HER2 in gastric and gastroesophageal cancer, including the prognostic relevance of HER2, the key differences between HER2 protein expression interpretation in breast and gastric cancer, the detection methods and the immunohistochemistry scoring system.

Entities: Disease Gene Species

Keywords: Gastric cancer; Human epidermal growth factor receptor 2 testing; Immunohistochemistry; Scoring system; Trastuzumab

Mesh：

Substances：

Year: 2016 PMID： 27217694 PMCID： PMC4870069 DOI： 10.3748/wjg.v22.i19.4619

Source DB: PubMed Journal: World J Gastroenterol ISSN： 1007-9327 Impact factor: 5.742

41 in total

1. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.

Authors: H Allgayer; R Babic; K U Gruetzner; A Tarabichi; F W Schildberg; M M Heiss
Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544

2. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity.

Authors: T Akiyama; C Sudo; H Ogawara; K Toyoshima; T Yamamoto
Journal: Science Date: 1986-06-27 Impact factor: 47.728

Review 3. Clinical impact of tumour biology in the management of gastroesophageal cancer.

Authors: Florian Lordick; Yelena Y Janjigian
Journal: Nat Rev Clin Oncol Date: 2016-03-01 Impact factor: 66.675

4. A comparison of equivocal immunohistochemical results with anti-HER2/neu antibodies A0485 and SP3 with corresponding FISH results in routine clinical practice.

Authors: Elizabeth Manion; Jason L Hornick; Susan C Lester; Jane E Brock
Journal: Am J Clin Pathol Date: 2011-06 Impact factor: 2.493

5. Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer.

Authors: Young Wha Koh; Hee Jin Lee; Jong Won Lee; Jun Kang; Gyungyub Gong
Journal: Mod Pathol Date: 2011-02-11 Impact factor: 7.842

6. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.

Authors: Lucas Faria Abrahão-Machado; Alexandre Andrade dos Anjos Jácome; Durval Renato Wohnrath; José Sebastião dos Santos; Estela Cristina Carneseca; José Humberto Tavares Guerreiro Fregnani; Cristovam Scapulatempo-Neto
Journal: World J Gastroenterol Date: 2013-10-14 Impact factor: 5.742

7. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.

Authors: Mark Barok; Minna Tanner; Katri Köninki; Jorma Isola
Journal: Cancer Lett Date: 2011-04-01 Impact factor: 8.679

8. Importance of EGF receptor, HER2/Neu and Erk1/2 kinase signalling for host cell elongation and scattering induced by the Helicobacter pylori CagA protein: antagonistic effects of the vacuolating cytotoxin VacA.

Authors: Nicole Tegtmeyer; Dana Zabler; Diana Schmidt; Roland Hartig; Sabine Brandt; Steffen Backert
Journal: Cell Microbiol Date: 2008-11-25 Impact factor: 3.715

9. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).

Authors: James E Boers; Harriëtte Meeuwissen; Natalie Methorst
Journal: Histopathology Date: 2011-02-16 Impact factor: 5.087

10. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.

Authors: Heike Grabsch; Shivan Sivakumar; Sally Gray; Helmut E Gabbert; Wolfram Müller
Journal: Cell Oncol Date: 2010 Impact factor: 6.730

71 in total

Review 1. Histology-agnostic drug development - considering issues beyond the tissue.

Authors: Roberto Carmagnani Pestana; Shiraj Sen; Brian P Hobbs; David S Hong
Journal: Nat Rev Clin Oncol Date: 2020-06-11 Impact factor: 66.675

2. HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features.

Authors: Rachel L Stewart; Justin E Caron; Evin H Gulbahce; Rachel E Factor; Katherine B Geiersbach; Erinn Downs-Kelly
Journal: Mod Pathol Date: 2017-07-28 Impact factor: 7.842

Review 3. Dealing with the gray zones in the management of gastric cancer: The consensus statement of the İstanbul Group.

Authors: Erman Aytaç; Fatih Aslan; Bahattin Çicek; Sibel Erdamar; Bengi Gürses; Koray Güven; Okan Falay; Tayfun Karahasanoğlu; Fatih Selçukbiricik; Uğur Selek; Banu Atalar; Emre Balık; Nurdan Tözün; İzzet Rozanes; Ali Arıcan; İsmail Hamzaoğlu; Bilgi Baca; Nil Molinas Mandel; Murat Saruç; Süha Göksel; Gökhan Demir; Fulya Ağaoğlu; Cengiz Yakıcıer; Uğur Özbek; Volkan Özben; Enis Özyar; Ahmet Levent Güner; Özlem Er; Kerim Kaban; Yasemin Bölükbaşı; Dursun Buğra; The İstanbul Group
Journal: Turk J Gastroenterol Date: 2019-07 Impact factor: 1.852

4. Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling.

Authors: Nehal Gupta; Sanjay K Srivastava
Journal: Mol Cancer Ther Date: 2019-07-03 Impact factor: 6.261

5. Targeted Next-Generation Sequencing Validates the Use of Diagnostic Biopsies as a Suitable Alternative to Resection Material for Mutation Screening in Colorectal Cancer.

Authors: Hersh A Ham-Karim; Henry Okuchukwu Ebili; Kirsty Manger; Wakkas Fadhil; Narmeen S Ahmad; Susan D Richman; Mohammad Ilyas
Journal: Mol Diagn Ther Date: 2019-06 Impact factor: 4.074